
Adrestia appoints Will Lewis as Chair, establishes US Operations and appoints new functional leads
Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced that it appointed William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors, Jennifer Millian, M.S., M.B.A. as VP of U.S. Operations, and Philip Coxon, Ph.D., as VP of Business Development. This extends Adrestia’s presence to the United States and deepens its drug development capabilities as it moves its emerging pipeline of first-in-class therapeutics towards the clinic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005044/en/
Will Lewis, Adrestia Chairman
“Adrestia’s leading synthetic rescue platform is systematically mining the human genome to find new ways of treating patients with currently intractable diseases” said Lewis. “The team unites world-class biology and drug discovery leadership with an exciting vision for genetic medicine. We are discovering new biology that opens fresh ways of thinking about tackling devastating diseases. Embracing the full complexity of human biology enables us to move on from ‘one disease, one target’ thinking, to instead using one drug to treat clusters of related diseases with related root causes. This platform is delivering, and I’m thrilled to help make this revolutionary new approach a reality for patients.”
“Adrestia welcomes Will, Jen and Phil as we execute on our vision: building a fully-integrated company that efficiently discovers, develops and commercializes new drugs for people suffering from rare and prevalent diseases with a genetic component,” said Robert Johnson, Chief Executive Officer of Adrestia. “Will’s track record of creating value through company-building is a precise fit for us, and his experience will be invaluable at this time of transformational progress for our company. Similarly, both Phil and Jen are seasoned functional specialists who will maximize the impact of our platform and steer our pipeline to the clinic.”
Will Lewis serves as Chair and Chief Executive Officer of Insmed, a global commercial-stage biopharmaceutical company based in New Jersey, U.S. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, which was acquired by Amryt in 2019. He previously spent more than 10 years working in investment banking in the U.S. and Europe at JP Morgan and Robertson Stevens. He also previously worked for the U.S. government. Will holds an MBA and a Juris Doctor with honors from Case Western Reserve University. He serves as the Chair of BioNJ, the life sciences association for New Jersey, and as a member of the Board of Trustees of Case Western Reserve University. He previously served as a member of the board of uniQure, a Netherlands-based biopharmaceutical company focused on gene therapy.
Jennifer Millian has 20 years’ experience of genetic disease drug development. She most recently served as VP of Program and Alliance Management at Boston, U.S.-based gene therapy developer Affinia Therapeutics developing novel neurologic and neuro-oncologic AAV-based gene therapies. Prior to that, she served in similar roles at uniQure and Sanofi Genzyme, where she worked for nearly 16 years after beginning her career in scientific roles. Jennifer holds an MBA from Nichols College and a Master’s degree from Worcester State College.
Dr. Phil Coxon brings nearly 15 years’ of business development experience within the Life Sciences sector. He joins from AstraZeneca where he was Senior Director of Transactions in Global Oncology Business Development and Licensing. Prior to that, he held various business development and alliance management roles in Global Business Development & Strategy at Teva Pharmaceuticals across all its therapeutic areas of interest, including neurology. He began his career in business development at LifeArc, a leading U.K. medical research charity. Phil received his Ph.D from The Institute of Cancer Research in London, where he also conducted post-doctoral work.
These appointments follow the recent addition of Professor John R.B. Perry as Adrestia’s Vice President, Human Genetics. His focus at Adrestia is translating his expertise in large-scale human population genomic analyses to identify and validate new targets emerging from Adrestia’s experimental biology platform. Dr. Perry is a world-renowned expert in human population genetics at the University of Cambridge who was involved in discovering many key genetic drivers of diverse complex diseases including obesity, Type 2 diabetes, reproductive disorders and aspects of behavior.
About Adrestia’s synthetic rescue platform
Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new approaches to treating intractable genetic diseases. The platform includes multiple components, each designed to yield new insights into how every gene in the human genome modifies a particular disease’s cellular phenotype. These insights are married with human genetic datasets to provide robust validation of new druggable targets and build an ever-growing synthetic rescue ‘Atlas’ of the human genome. As the Atlas expands, the opportunities to use synthetic rescue drugs to treat both rare and common diseases continue to grow.
This scalable platform builds on decades of research by Professor Steve Jackson’s laboratory at the University of Cambridge into synthetic rescue and the related concept of synthetic lethality for the treatment of cancer. The Jackson Laboratory’s work has yielded a wealth of concepts, techniques, and know-how, now translated into Adrestia’s platform.
About Adrestia
Adrestia is a leader in synthetic rescue therapies for genetic diseases. As many directly causative mutations are not druggable, synthetic rescue embraces the much broader target set represented by functionally connected genes, to correct the effects of the causative mutations and ‘rescue’ health. Adrestia is creating a synthetic rescue ‘Atlas’ of the human genome and advancing a portfolio of first-in-class therapies, initially for neurologic, neuromuscular and cardiomyopathic diseases. Adrestia’s platform and in-house programs are complemented by a target discovery alliance with GSK and a Huntington’s disease collaboration with noted researchers including Dr Sarah Tabrizi at University College London.
Adrestia was co-founded by Professor Steve Jackson and the deep technology investment fund Ahren Innovation Capital, which co-led Adrestia’s Series A financing along with GSK. Jackson co-originated the first synthetic lethality drug, olaparib, which was the first drug approved to treat cancers caused by inherited mutations. For further information, visit: www.adrestia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005044/en/
Contact information
Investors
Robert Johnson
investors@adrestia.com
Media
Tom Donovan
tom@lyrebird.bio
+1 857 559 3397
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo